These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32478597)

  • 1. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation.
    Van Daele R; Spriet I; Maertens J
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):539-550. PubMed ID: 32478597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posaconazole in immunocompromised pediatric patients.
    Vicenzi EB; Cesaro S
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):543-553. PubMed ID: 29912581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posaconazole: an oral triazole with an extended spectrum of activity.
    Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
    Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
    Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
    Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Posaconazole.
    Chen L; Krekels EHJ; Verweij PE; Buil JB; Knibbe CAJ; Brüggemann RJM
    Drugs; 2020 May; 80(7):671-695. PubMed ID: 32323222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
    Oh J; Kang CI; Kim SH; Huh K; Cho SY; Chung DR; Lee SY; Jung CW; Peck KR
    Mycoses; 2020 Jan; 63(1):89-94. PubMed ID: 31610064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
    Clark NM; Grim SA; Lynch JP
    Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.
    Girmenia C; Iori AP
    Expert Opin Drug Saf; 2017 Mar; 16(3):329-339. PubMed ID: 28004589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection.
    Kim JH; Benefield RJ; Ditolla K
    Mycoses; 2016 Nov; 59(11):726-733. PubMed ID: 27392814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients.
    John J; Loo A; Mazur S; Walsh TJ
    Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):881-895. PubMed ID: 31550939
    [No Abstract]   [Full Text] [Related]  

  • 13. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
    Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
    J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.
    Cojutti PG; Candoni A; Lazzarotto D; Rabassi N; Fanin R; Hope W; Pea F
    Br J Clin Pharmacol; 2018 Nov; 84(11):2544-2550. PubMed ID: 29975796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
    Elkayal O; Spriet I; Uyttebroeck A; Colita A; Annaert P; Allegaert K; Smits A; Van Daele R; Dreesen E
    Ther Drug Monit; 2021 Aug; 43(4):512-518. PubMed ID: 33560094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole liquid vs tablet formulation in lung transplant recipients.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
    Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
    PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
    McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
    Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.